Clinical Trials Browser

Laryngeal Neoplasms × tislelizumab × Head & Neck × Clear all

NCT06554028 2024-08-14

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Phase 2 Not yet recruiting

Hypopharyngeal Neoplasms, Laryngeal Neoplasms